By [Your Name/Journalistic Staff]
October 13, 2025
The moment a physician utters the words "Stage 4 breast cancer," the world as the patient knows it effectively ceases to exist. For Miriam Sabo, that moment arrived at age 42, an age typically associated with the mid-career climb, parenting school-aged children, and planning for a long-term future. Instead, Sabo found herself part of a small, often overlooked demographic: those diagnosed with de novo metastatic breast cancer (MBC).
In her case, the cancer had already metastasized to her liver by the time of her initial diagnosis. This is the reality for roughly 6% of all breast cancer patients, where the disease is systemic from the outset. Unlike early-stage breast cancer, which is often treated with the goal of eradication, de novo MBC presents a different, more daunting challenge: a diagnosis that will never truly go into remission.
The Reality of a Non-Curative Diagnosis
For Sabo, the standard cultural narrative of the "cancer warrior"—often characterized by boxing gloves, "beat it" slogans, and the promise of total recovery—felt not only alienating but fundamentally dishonest.
"I personally try to stay away from the word terminal and prefer non-curative," Sabo explains. "Nothing prepares you for the realization that you will be in treatment forever—however long my ‘forever’ is going to be."
This shift in perspective is crucial for patients navigating the psychological landscape of MBC. The medical community is increasingly recognizing that the "battle" metaphor can be detrimental to those who cannot "win" in the traditional sense. Instead, the objective shifts toward chronic disease management, quality of life, and the pursuit of longevity through precision medicine and supportive care. Sabo’s advice to others in her position is categorical: "The statistics should never be Googled."
A Chronology of Resilience: 6.5 Years and Counting
The trajectory of Sabo’s life since her 2019 diagnosis has been defined by a refusal to be reduced to a clinical data point.
- The Initial Shock: Upon receiving the diagnosis, the immediate priority was securing a support network. Having previously interacted with Sharsheret—a national non-profit organization supporting Jewish women and families facing breast cancer—regarding BRCA testing, Sabo knew exactly where to turn.
- Building the Team: Sharsheret provided more than just medical navigation; they provided a psychological anchor. Sabo was paired with a social worker who served as a sounding board during the chaotic initial weeks of diagnosis and treatment planning.
- Finding Purpose in Peer Support: Encouraged by the organization’s leadership, specifically within the "Embrace" program, Sabo transitioned from patient to peer supporter. By mentoring other women navigating the complexities of MBC, she transformed her personal trauma into a mechanism for communal healing.
- The Long Game: Six and a half years post-diagnosis, Sabo has reached milestones that, at the time of her diagnosis, felt like statistical improbabilities. She has witnessed her four children grow, celebrated high school and college graduations, and guided two of her children through their own weddings.
Supporting Data: The Landscape of MBC
Metastatic breast cancer remains the leading cause of breast cancer-related deaths. According to the American Cancer Society and the Metastatic Breast Cancer Network, while the five-year relative survival rate for localized breast cancer is nearly 99%, that rate drops significantly when the cancer has spread to distant parts of the body.
However, these figures are historical averages. The landscape of MBC is changing rapidly due to:
- Targeted Therapies: The development of CDK4/6 inhibitors and other targeted treatments has significantly extended progression-free survival for many patients.
- Multidisciplinary Care: The "team" approach, which includes oncologists, nutritionists, mental health professionals, and peer support groups, is now recognized as a standard of care for improving patient outcomes.
- Psychosocial Support: Organizations like Sharsheret play a vital role in addressing the "hidden" symptoms of cancer—anxiety, depression, and the existential dread that accompanies a chronic, life-limiting illness.
The Role of Supportive Care: Insights from Sharsheret
Sharsheret’s "Embrace" program is specifically designed for women living with advanced breast cancer. It recognizes that the needs of an MBC patient are distinct from those of a patient in the curative setting.
In an official capacity, advocates emphasize that "living with" rather than "dying from" is the goal. By connecting patients with others who share their specific diagnosis, organizations help mitigate the profound sense of isolation that often accompanies Stage 4 disease. Peer support allows for the practical exchange of information—such as how to manage side effects of chemotherapy or how to discuss a diagnosis with children—that medical professionals may not have the time or specialized training to address.
Implications: Changing the Cultural Narrative
Sabo’s story has profound implications for how society treats and perceives those with chronic, terminal, or non-curative illnesses.
1. Reframing the "Expiration Date"
Sabo’s personal motto—"I’m not milk; there’s no expiration date stamped on me"—serves as a radical act of defiance against a medical establishment that often relies on rigid actuarial tables. Her experience highlights the importance of individualized prognosis rather than population-based statistics.
2. The Power of Faith and Community
For many patients, medical treatment is only one pillar of survival. Sabo emphasizes that her faith provides the strength to endure the most grueling moments of her treatment. "I hold onto my faith that G-d’s plans are always for good, even in the hardest of moments," she reflects. This internal fortitude, bolstered by the external support of her community, has been instrumental in her capacity to remain present for the "day-in and day-out moments" of family life.
3. The Future of Advocacy
The shift toward supporting those with metastatic disease represents a maturing of the breast cancer advocacy movement. Early efforts were largely focused on awareness and screening; today, the focus is increasingly on equity, access to innovative treatments, and the dignity of those living with metastatic disease.
Conclusion: Living in the "Forever"
Miriam Sabo’s journey is a testament to the fact that a Stage 4 diagnosis is not the end of the narrative, but rather the beginning of a different, more intentional way of living. By rejecting the term "terminal" in favor of "non-curative," and by choosing to focus on the moments that define a life—rather than the statistics that attempt to predict its end—Sabo continues to thrive.
Her story reminds us that while we cannot always control the biological realities of our health, we retain the agency to define how we walk through those realities. For the thousands of women currently navigating the complexities of metastatic breast cancer, Sabo’s life offers a beacon of hope: the future is not always a fixed point, and the "forever" we are given, however long it may be, is ours to shape.
About the Author
